OKC clinical trials company awarded Phase III COVID-19 Vaccine Trial

OKLAHOMA CITY (KOKH) — The Lynn Health Science Institute in Oklahoma City has been awarded the Moderna Phase III COVID-19 Vaccine Study slated to commence July 1, 2020.

The study is a 24-month long study for healthy individuals age 18 and above.

Board-certified physician, Carl Griffin, M.D., has more than 20 years of experience conducting clinical trials in Oklahoma City and will serve as the principal investigator for the study.

The study will determine if participants receiving the potential vaccine develop antibodies that contribute to virus resistance for COVID-19.

Interested participants must meet the inclusion and exclusion criteria established by Moderna, Inc. You can find the participation form here.

If successful, the data from this trial could lead to the development of the first vaccine for COVID-19.

Participants who have been diagnosed with active COVID-19, or recovered from a COVID-19 infection are not eligible to participate in the study.

Over the course of the study, qualified participants will receive two vaccinations and be monitored for the remainder of the study.